Published in Medical Letter on the CDC and FDA, July 24th, 2005
Foradil Certihaler was co-developed by SkyePharma PLC and Novartis Pharma AG and is a trademark of Novartis. Foradil Certihaler was submitted for regulatory review in Europe on a country-by-country basis beginning in December 2002 and has now been approved in Switzerland, Austria, Finland, Portugal and the Netherlands as well as in Germany. It has also been approved in 5 countries in Latin America. It was also submitted for regulatory review...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.